Wlanholding Leads $3M Investment as Dr. Lanthaler Becomes Chairman of aTENSION.life
Dr. Werner Lanthaler, the driving force behind Wlanholding GmbH, has recently been appointed the Chairman of aTENSION.life, a pioneering startup in the high-tech life sciences sector focused on hypertension diagnostics. This appointment comes on the heels of a significant USD 3 million seed funding round, predominantly led by Wlanholding, alongside eQventure and VP Venture Partners serving as co-investors.
\. . .
The innovative firm aTENSION.life aims to revolutionize the way hypertension is diagnosed and managed by utilizing advanced mass spectrometry techniques within its proprietary ALDO+ technology platform. This platform seeks to make essential diagnostic tools more accessible for individuals suffering from uncontrolled hypertension, a condition that continues to impact millions worldwide.
The first groundbreaking product from aTENSION.life, known as ALDO+PA, is specifically designed to screen for primary aldosteronism. This condition is often overlooked, affecting an estimated 5-10% of individuals with hypertension. Dr. Lanthaler, commenting on this pivotal moment for aTENSION.life, emphasized the necessity for early diagnoses and targeted treatments for hypertension patients. He expressed confidence that this funding would catalyze the widespread adoption of clinical mass spectrometry diagnostics, making them available to a broader audience.
Dr. Lanthaler's vision for aTENSION.life aligns closely with his broader commitment to advancing transformative technologies within the life sciences. With his guidance, the company aims to tap into a substantial market potential, addressing the challenges faced by approximately 1.3 billion adults globally affected by hypertension, of whom 720 million are reportedly inadequately treated due to underdiagnosis of various hypertension subtypes.
Currently, the ALDO+PA test has been launched in Austria through a strategic partnership with labors.at, with plans to expand its reach to the DACH region by 2026. Notably, some early adopters have already begun implementing this innovative diagnostic technology across Germany, Switzerland, and the United States. Along with the strategic direction that Dr. Lanthaler will provide, he will be collaborating closely with the recently established management team at aTENSION.life, which includes Bernhard Klemen (CEO), Marko Poglitsch (CSO), and Katharina Wieser (CBO).
A closer look at Wlanholding GmbH reveals a family office deeply committed to making strategic investments and offering advisory services specifically within the life sciences and high-tech sustainability sectors. Dr. Lanthaler, formerly the CEO of Evotec SE, is known for his dedication to supporting passionate entrepreneurs and management teams, aiming to transform innovative concepts into scalable ventures that have a global impact.
As for aTENSION.life, this company represents a significant leap forward in hypertension care. By prioritizing accessibility to advanced diagnostics, it sets a new benchmark in precision medicine. The ALDO+ technology platform holds the promise of enabling targeted therapeutic approaches by simply utilizing a single blood sample for testing, thereby paving the way for improved patient outcomes.
As the medical landscape continues to evolve, the role of enhancing diagnostic capabilities becomes ever more critical. The leadership transition at aTENSION.life not only signifies a bold step in addressing pressing healthcare issues but also reflects a broader trend towards innovation and collaboration within the life sciences sector.
Dr. Lanthaler's appointment as Chairman is a testament to his visionary approach and a strategic signal that aTENSION.life is poised to further its mission to bring precision healthcare solutions to the forefront of medical practice. With significant investment backing and a strong leadership team, aTENSION.life is well-positioned to lead the charge in hypertension diagnostics and ultimately contribute to better health outcomes for millions around the globe.
\. . .
The innovative firm aTENSION.life aims to revolutionize the way hypertension is diagnosed and managed by utilizing advanced mass spectrometry techniques within its proprietary ALDO+ technology platform. This platform seeks to make essential diagnostic tools more accessible for individuals suffering from uncontrolled hypertension, a condition that continues to impact millions worldwide.
The first groundbreaking product from aTENSION.life, known as ALDO+PA, is specifically designed to screen for primary aldosteronism. This condition is often overlooked, affecting an estimated 5-10% of individuals with hypertension. Dr. Lanthaler, commenting on this pivotal moment for aTENSION.life, emphasized the necessity for early diagnoses and targeted treatments for hypertension patients. He expressed confidence that this funding would catalyze the widespread adoption of clinical mass spectrometry diagnostics, making them available to a broader audience.
Dr. Lanthaler's vision for aTENSION.life aligns closely with his broader commitment to advancing transformative technologies within the life sciences. With his guidance, the company aims to tap into a substantial market potential, addressing the challenges faced by approximately 1.3 billion adults globally affected by hypertension, of whom 720 million are reportedly inadequately treated due to underdiagnosis of various hypertension subtypes.
Currently, the ALDO+PA test has been launched in Austria through a strategic partnership with labors.at, with plans to expand its reach to the DACH region by 2026. Notably, some early adopters have already begun implementing this innovative diagnostic technology across Germany, Switzerland, and the United States. Along with the strategic direction that Dr. Lanthaler will provide, he will be collaborating closely with the recently established management team at aTENSION.life, which includes Bernhard Klemen (CEO), Marko Poglitsch (CSO), and Katharina Wieser (CBO).
A closer look at Wlanholding GmbH reveals a family office deeply committed to making strategic investments and offering advisory services specifically within the life sciences and high-tech sustainability sectors. Dr. Lanthaler, formerly the CEO of Evotec SE, is known for his dedication to supporting passionate entrepreneurs and management teams, aiming to transform innovative concepts into scalable ventures that have a global impact.
As for aTENSION.life, this company represents a significant leap forward in hypertension care. By prioritizing accessibility to advanced diagnostics, it sets a new benchmark in precision medicine. The ALDO+ technology platform holds the promise of enabling targeted therapeutic approaches by simply utilizing a single blood sample for testing, thereby paving the way for improved patient outcomes.
As the medical landscape continues to evolve, the role of enhancing diagnostic capabilities becomes ever more critical. The leadership transition at aTENSION.life not only signifies a bold step in addressing pressing healthcare issues but also reflects a broader trend towards innovation and collaboration within the life sciences sector.
Dr. Lanthaler's appointment as Chairman is a testament to his visionary approach and a strategic signal that aTENSION.life is poised to further its mission to bring precision healthcare solutions to the forefront of medical practice. With significant investment backing and a strong leadership team, aTENSION.life is well-positioned to lead the charge in hypertension diagnostics and ultimately contribute to better health outcomes for millions around the globe.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.